265 related articles for article (PubMed ID: 33819109)
1. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
2. Complex survival trial design by the product integration method.
Tang Y
Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
[TBL] [Abstract][Full Text] [Related]
3. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
4. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
5. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
[TBL] [Abstract][Full Text] [Related]
6. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
7. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
8. Are restricted mean survival time methods especially useful for noninferiority trials?
Freidlin B; Hu C; Korn EL
Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
[TBL] [Abstract][Full Text] [Related]
9. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
10. On sample size calculation for comparing survival curves under general hypothesis testing.
Jung SH; Chow SC
J Biopharm Stat; 2012; 22(3):485-95. PubMed ID: 22416836
[TBL] [Abstract][Full Text] [Related]
11. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
12. Sample size determination for comparing several survival curves with unequal allocations.
Halabi S; Singh B
Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
[TBL] [Abstract][Full Text] [Related]
13. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
14. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
Phadnis MA; Mayo MS
Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
[TBL] [Abstract][Full Text] [Related]
15. A sample size formula for the supremum log-rank statistic.
Eng KH; Kosorok MR
Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
[TBL] [Abstract][Full Text] [Related]
16. Sample size calculation for the proportional hazards cure model.
Wang S; Zhang J; Lu W
Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
[TBL] [Abstract][Full Text] [Related]
17. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
18. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Phadnis MA; Wetmore JB; Mayo MS
Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
[TBL] [Abstract][Full Text] [Related]
20. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
